Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPTABLE: Aspirin Dosing in ASCVD
NCT02697916Phase 3Completed
- Sponsor
- Duke University
- Start
- Apr 2016
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in atherosclerotic cardiovascular disease (ASCVD) (2 arms), sponsored by Duke University. Primary endpoint: Composite of All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke at 4 years. Started Apr 2016; status: completed.
02
Drugs
aspirin
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT02697916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697916.